This trial is testing a new drug to see if it is safe and effective for treating advanced or metastatic solid tumors.
3 Primary · 5 Secondary · Reporting Duration: up to 100 days post last dose
Experimental Treatment
132 Total Participants · 1 Treatment Group
Primary Treatment: TJ033721 · No Placebo Group · Phase 1
Age 18+ · All Participants · 4 Total Inclusion Criteria
Mark “Yes” if the following statements are true for you: